At its September 2026 intracycle meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended changes to the Pharmaceutical Benefits Scheme (PBS) restrictions for 14 low-cost antidepressants. The recommended changes would broaden PBS-subsidised access to these medicines to better reflect contemporary Australian clinical practice.
The antidepressants considered were citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mianserin, mirtazapine, moclobemide, nortriptyline, paroxetine, sertraline and venlafaxine.
The PBAC Public Summary Document for this item is now available on the Review of low-cost PBS-listed antidepressants webpage.
If you have any questions relating to this item, please email PBSpostmarket@health.gov.au.